AI improves radiologist accuracy, reduces false-positive findings

AI-powered software can help radiologists identify malignant lung cancers with improved accuracy, according to new research published in Radiology.

The study’s authors explored data from four different hospitals, including 600 randomly selected chest x-rays featuring at least one malignant lung nodule and another 200 normal chest x-rays. All exams occurred between October 2015 and September 2017.

A group of radiologists then read each study twice—once on their own and once with assistance from a deep convolutional neural network (DCNN) trained specifically to detect lung nodules. The DCNN was trained on more than 13,000 normal x-rays and another 3,500 x-rays containing lung nodules.

Overall, the radiologists saw their average false-positive findings drop from 0.2 per x-ray to 0.18 per x-ray and average sensitivity jump from 65.1% to 70.3%.

“Computer-aided detection software to detect lung nodules has not been widely accepted and utilized because of high false positive rates, even though it provides relatively high sensitivity,” co-author Byoung Wook Choi, MD, PhD, department of radiology at the Yonsei University Health System in Seoul, Korea, said in a prepared statement. “DCNN may be a solution to reduce the number of false positives.”

The authors did note that their research had several limitations. For example, their dataset was “prone to spectrum bias” because certain images showing benign nodules were removed before the study began. In addition, no specific time was established that had to occur between the radiologists’ two interpretations, “leading to the possibility of recall bias.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.